GE Healthcare of Chalfont St. Giles, U.K., and Nycomed of Zurich, Switzerland, are expanding their partnership in Russia and the Commonwealth of Independent States for the local sales, marketing, and distribution of GE Healthcare's contrast agents in that region.
The agreement also will create a new Moscow-based company to handle GE's CT, x-ray, and MRI contrast media products. The new company will have approximately 40 employees in its Moscow offices and across the region.
The joint venture is expected to become operational in the second half of this year.
Related Reading
GE targets ultrasound energy reduction, April 26, 2010
Report: GE ignored Omniscan warnings, April 19, 2010
GE touts research on PET agent, April 12, 2010
GE settles NSF case with Calif. woman, March 25, 2010
Acusphere, Nycomed ink European partnership, July 7, 2004
Copyright © 2010 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
